Baidu
map

Blood:AGK缺陷可导致巨核细胞分化异常和血小板减少症

2020-03-24 MedSci原创 MedSci原创

AGK通过维持JAK2/Stat3信号激活来调节巨核细胞分化,而AGK缺乏会导致血小板减少。 肽617F通过促进AGK和JAK2的结合放大JAK2/Stat3信号,加速巨核细胞分化。

巨核细胞发育异常和血小板生成异常会导致血小板减少症或血小板增多症,增加出血或血栓形成风险。AGK是一种线粒体膜激酶,可催化磷脂酸和溶血磷脂酸的形成。现已明确AGK突变是Sengers综合征的主要原因,且有报道,Sengers综合征患者表现出血小板减少。

在本研究中,研究人员发现巨核细胞/血小板特异性AGK缺陷小鼠会发展成血小板减少症和脾肿大,主要由无效的骨髓血小板生成和过多的髓外造血引起的,但与循环血小板凋亡无关。

据报道,G126E突变会减弱AGK激酶活性。研究人员发现AGK G126E突变不影响外周血血小板计数或巨核细胞分化,表明AGK参与巨核细胞发育和血小板生物发生并不依赖于其激酶活性。

Mpl/JAK2/Stat3通路是调节巨核细胞发育的主要信号通路。

本研究证实,AGK可以与巨核细胞/血小板中的JAK2结合。此外,研究人员发现JAK2 V617F突变显着增强了AGK与JAK2的结合,并极大地促进了巨核细胞/血小板对血小板生成素刺激时的JAK2/Stat3信号传导。研究人员还发现JAK2 JH2结构域肽YGVCF617CGDENI序列能增强AGK与JAK2的结合,而且包含YGVCF617CGDENI序列的可渗透细胞肽加速了血小板的形成。

总而言之,本研究揭示了AGK在巨核细胞分化和血小板生物发生中的至关重要的作用,提示靶向AGK和JAK2之间的相关作用或可成为血小板减少症或血小板增多症的新治疗测序。

原始出处:

Haojie Jiang, et l. The role of AGK in thrombocytopoiesis and possible therapeutic strategies. Blood. March 20, 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954033, encodeId=76431954033dc, content=<a href='/topic/show?id=024f210298' target=_blank style='color:#2F92EE;'>#AGK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2102, encryptionId=024f210298, topicName=AGK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 10 18:47:07 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981526, encodeId=b1b119815267a, content=<a href='/topic/show?id=786f482021f' target=_blank style='color:#2F92EE;'>#巨核细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48202, encryptionId=786f482021f, topicName=巨核细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Jul 30 18:47:07 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302840, encodeId=500b130284012, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490280, encodeId=07ab149028075, content=<a href='/topic/show?id=af9f48201a9' target=_blank style='color:#2F92EE;'>#巨核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48201, encryptionId=af9f48201a9, topicName=巨核细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3d78715376, createdName=liuquan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570285, encodeId=dacf15e02855a, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
    2020-09-10 仁医06
  2. [GetPortalCommentsPageByObjectIdResponse(id=1954033, encodeId=76431954033dc, content=<a href='/topic/show?id=024f210298' target=_blank style='color:#2F92EE;'>#AGK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2102, encryptionId=024f210298, topicName=AGK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 10 18:47:07 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981526, encodeId=b1b119815267a, content=<a href='/topic/show?id=786f482021f' target=_blank style='color:#2F92EE;'>#巨核细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48202, encryptionId=786f482021f, topicName=巨核细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Jul 30 18:47:07 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302840, encodeId=500b130284012, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490280, encodeId=07ab149028075, content=<a href='/topic/show?id=af9f48201a9' target=_blank style='color:#2F92EE;'>#巨核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48201, encryptionId=af9f48201a9, topicName=巨核细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3d78715376, createdName=liuquan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570285, encodeId=dacf15e02855a, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1954033, encodeId=76431954033dc, content=<a href='/topic/show?id=024f210298' target=_blank style='color:#2F92EE;'>#AGK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2102, encryptionId=024f210298, topicName=AGK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 10 18:47:07 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981526, encodeId=b1b119815267a, content=<a href='/topic/show?id=786f482021f' target=_blank style='color:#2F92EE;'>#巨核细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48202, encryptionId=786f482021f, topicName=巨核细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Jul 30 18:47:07 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302840, encodeId=500b130284012, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490280, encodeId=07ab149028075, content=<a href='/topic/show?id=af9f48201a9' target=_blank style='color:#2F92EE;'>#巨核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48201, encryptionId=af9f48201a9, topicName=巨核细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3d78715376, createdName=liuquan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570285, encodeId=dacf15e02855a, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1954033, encodeId=76431954033dc, content=<a href='/topic/show?id=024f210298' target=_blank style='color:#2F92EE;'>#AGK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2102, encryptionId=024f210298, topicName=AGK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 10 18:47:07 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981526, encodeId=b1b119815267a, content=<a href='/topic/show?id=786f482021f' target=_blank style='color:#2F92EE;'>#巨核细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48202, encryptionId=786f482021f, topicName=巨核细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Jul 30 18:47:07 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302840, encodeId=500b130284012, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490280, encodeId=07ab149028075, content=<a href='/topic/show?id=af9f48201a9' target=_blank style='color:#2F92EE;'>#巨核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48201, encryptionId=af9f48201a9, topicName=巨核细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3d78715376, createdName=liuquan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570285, encodeId=dacf15e02855a, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1954033, encodeId=76431954033dc, content=<a href='/topic/show?id=024f210298' target=_blank style='color:#2F92EE;'>#AGK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2102, encryptionId=024f210298, topicName=AGK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 10 18:47:07 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981526, encodeId=b1b119815267a, content=<a href='/topic/show?id=786f482021f' target=_blank style='color:#2F92EE;'>#巨核细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48202, encryptionId=786f482021f, topicName=巨核细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Jul 30 18:47:07 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302840, encodeId=500b130284012, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490280, encodeId=07ab149028075, content=<a href='/topic/show?id=af9f48201a9' target=_blank style='color:#2F92EE;'>#巨核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48201, encryptionId=af9f48201a9, topicName=巨核细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3d78715376, createdName=liuquan, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570285, encodeId=dacf15e02855a, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Thu Mar 26 08:47:07 CST 2020, time=2020-03-26, status=1, ipAttribution=)]

相关资讯

关于《肿瘤化疗所致血小板减少症诊疗中国专家共识(2018版)》的九个问题

肿瘤化疗所致血小板减少症(Chemotherapy induced thrombocytopenia,CIN)是指抗肿瘤化疗药物对骨髓产生抑制,导致外周血中血小板计数低于正常值的一种常见的肿瘤治疗并发症,是临床常见的血液学毒性反应。2018年9月,中国临床肿瘤学会发布最新版的《肿瘤化疗所致血小板减少症诊疗中国专家共识》,是以2014年版本的修订和更新。时隔四年,看一看新版有哪些要点呢?01为什么会

FDA批准Shionogi的Mulpleta治疗慢性肝病引起的血小板减少症

美国食品和药物管理局(FDA)近日宣布批准Shionogi的Mulpleta(lusutrombopag)用于治疗慢性肝病引起的成人血小板减少症。FDA于今年2月份接受了血小板生成素受体激动剂Mulpleta的申请,并授予其优先审查资格。

欧盟批准Lusutrombopag用于治疗严重血小板减少症

欧洲委员会(EC)已批准Shionogi公司的lusutrombopag用于治疗正在接受侵入性手术的慢性肝病(CLD)成人患者的严重血小板减少症。

人工股骨头置换术后肝素诱发血小板减少症1例

肝素是预防和治疗血栓性疾病常用药物之一,而血小板减少症是其容易漏诊、误诊、发病隐匿而且极为罕见的并发症,即肝素诱发血小板减少症(HIT)。HIT的特点是血小板减少,伴或不伴有动静脉血栓形成,其致残率和死亡率很高,在临床医师应有足够的认识和重视。笔者回顾性分析于2018-02-20诊治的1例人工股骨头置换术后HIT患者临床资料,并对相关文献进行复习总结,报道如下。

Shionogi宣布在英国推出血小板生成素受体激动剂Mulpleo(lusutrombopag),用于接受侵入性治疗的慢性肝病成年患者的严重血小板减少症

盐野义制药有限公司(Shionogi)宣布在英国推出Mulpleo(lusutrombopag),用于接受侵入性治疗的慢性肝病(CLD)成年患者的严重血小板减少症。

J Thromb Haemost:Avatrombopag增加肝脏疾病所致的血小板减少症患者血小板计数但不增加血小板活化

由此可见,在这项血小板减少症的CLD患者随机、双盲、安慰剂对照、平行组研究中,avatrombopag增加了血小板计数,但没有增加体内血小板活化或体外血小板反应性。

Baidu
map
Baidu
map
Baidu
map